127 related articles for article (PubMed ID: 7927807)
1. Enhancement of anti-Shigella lipopolysaccharide (LPS) response by addition of the cholera toxin B subunit to oral and intranasal proteosome-Shigella flexneri 2a LPS vaccines.
Orr N; Arnon R; Rubin G; Cohen D; Bercovier H; Lowell GH
Infect Immun; 1994 Nov; 62(11):5198-200. PubMed ID: 7927807
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models.
Orr N; Robin G; Cohen D; Arnon R; Lowell GH
Infect Immun; 1993 Jun; 61(6):2390-5. PubMed ID: 8500877
[TBL] [Abstract][Full Text] [Related]
3. Native and mutant forms of cholera toxin and heat-labile enterotoxin effectively enhance protective efficacy of live attenuated and heat-killed Shigella vaccines.
Hartman AB; Van De Verg LL; Venkatesan MM
Infect Immun; 1999 Nov; 67(11):5841-7. PubMed ID: 10531238
[TBL] [Abstract][Full Text] [Related]
4. DeltaguaBA attenuated Shigella flexneri 2a strain CVD 1204 as a Shigella vaccine and as a live mucosal delivery system for fragment C of tetanus toxin.
Anderson RJ; Pasetti MF; Sztein MB; Levine MM; Noriega FR
Vaccine; 2000 Apr; 18(21):2193-202. PubMed ID: 10717338
[TBL] [Abstract][Full Text] [Related]
5. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.
Robin G; Keisari Y; Slepon R; Ashkenazi S; Cohen D
Vaccine; 1999 Aug; 17(23-24):3109-15. PubMed ID: 10462247
[TBL] [Abstract][Full Text] [Related]
6. Antigen-specific B memory cell responses to lipopolysaccharide (LPS) and invasion plasmid antigen (Ipa) B elicited in volunteers vaccinated with live-attenuated Shigella flexneri 2a vaccine candidates.
Simon JK; Wahid R; Maciel M; Picking WL; Kotloff KL; Levine MM; Sztein MB
Vaccine; 2009 Jan; 27(4):565-72. PubMed ID: 19022324
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults.
Fries LF; Montemarano AD; Mallett CP; Taylor DN; Hale TL; Lowell GH
Infect Immun; 2001 Jul; 69(7):4545-53. PubMed ID: 11401998
[TBL] [Abstract][Full Text] [Related]
8. Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection.
Mallett CP; Hale TL; Kaminski RW; Larsen T; Orr N; Cohen D; Lowell GH
Infect Immun; 1995 Jun; 63(6):2382-6. PubMed ID: 7768627
[TBL] [Abstract][Full Text] [Related]
9. [The antigenic and immunogenic properties of the bivalent strain Shigella flexneri-Shigella sonnei 1 No. 200].
Bondarenko VM; Nikolaeva AI; Marakusha BI; Belova TS
Zh Mikrobiol Epidemiol Immunobiol; 1995; (6):47-8. PubMed ID: 8553752
[No Abstract] [Full Text] [Related]
10. Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine.
Kaminski RW; Wu M; Turbyfill KR; Clarkson K; Tai B; Bourgeois AL; Van De Verg LL; Walker RI; Oaks EV
Clin Vaccine Immunol; 2014 Mar; 21(3):366-82. PubMed ID: 24403527
[TBL] [Abstract][Full Text] [Related]
11. A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection.
Phalipon A; Tanguy M; Grandjean C; Guerreiro C; Bélot F; Cohen D; Sansonetti PJ; Mulard LA
J Immunol; 2009 Feb; 182(4):2241-7. PubMed ID: 19201878
[TBL] [Abstract][Full Text] [Related]
12. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.
Oaks EV; Turbyfill KR
Vaccine; 2006 Mar; 24(13):2290-301. PubMed ID: 16364513
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine.
Riddle MS; Kaminski RW; Williams C; Porter C; Baqar S; Kordis A; Gilliland T; Lapa J; Coughlin M; Soltis C; Jones E; Saunders J; Keiser PB; Ranallo RT; Gormley R; Nelson M; Turbyfill KR; Tribble D; Oaks EV
Vaccine; 2011 Sep; 29(40):7009-19. PubMed ID: 21787825
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids.
Taylor DN; Trofa AC; Sadoff J; Chu C; Bryla D; Shiloach J; Cohen D; Ashkenazi S; Lerman Y; Egan W
Infect Immun; 1993 Sep; 61(9):3678-87. PubMed ID: 8359890
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and protective efficacy offered by a ribosomal-based vaccine from Shigella flexneri 2a.
Shim DH; Chang SY; Park SM; Jang H; Carbis R; Czerkinsky C; Uematsu S; Akira S; Kweon MN
Vaccine; 2007 Jun; 25(25):4828-36. PubMed ID: 17507120
[TBL] [Abstract][Full Text] [Related]
16. [Expression of S.sonnei form I antigen gene and V.cholerae toxin B subunit gene in S.flexneri 2a strain and investigation of their immunoprotective response in mice].
Qian F; Rui X; Su G; Huang C
Yi Chuan Xue Bao; 1996; 23(4):322-8. PubMed ID: 8950856
[TBL] [Abstract][Full Text] [Related]
17. Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG.
Kotloff KL; Noriega F; Losonsky GA; Sztein MB; Wasserman SS; Nataro JP; Levine MM
Infect Immun; 1996 Nov; 64(11):4542-8. PubMed ID: 8890204
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Shigella vaccine safety and efficacy in an intranasally challenged mouse model.
Mallett CP; VanDeVerg L; Collins HH; Hale TL
Vaccine; 1993; 11(2):190-6. PubMed ID: 8438617
[TBL] [Abstract][Full Text] [Related]
19. Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination.
Cohen D; Orr N; Robin G; Slepon R; Ashkenazi S; Ashkenazi I; Shemer J
Clin Diagn Lab Immunol; 1996 Jul; 3(4):451-5. PubMed ID: 8807212
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of the live oral auxotrophic Shigella flexneri SFL124 in adult Vietnamese volunteers.
Li A; Kärnell A; Huan PT; Cam PD; Minh NB; Trâm LN; Quy NP; Trach DD; Karlsson K; Lindberg G
Vaccine; 1993; 11(2):180-9. PubMed ID: 8438616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
